COMMUNIQUÉS West-GlobeNewswire

Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World’s First CGM System with No On-body Component
26/10/2026
First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics’ innovation roadmap, with potential launch in 2028 Built on the proven sensing technology behind [...]
Stryker completes acquisition of ZuriMED to enhance its shoulder offering
26/10/2026
Portage, Michigan, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Stryker has completed its acquisition of ZuriMED, adding the FiberLocker System to its Sports Medicine portfolio The acquisition adds a commercialized rotator cuff [...]
GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting
26/10/2026
SAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company [...]
Certara to Report Third Quarter 2026 Financial Results on November 5th, 2026
26/10/2026
RADNOR, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2026 [...]
Seismic Therapeutic to Participate in Upcoming Investor Conferences
26/10/2026
WATERTOWN, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Seismic Therapeutic, Inc. today announced that company management will participate in the following investor conferences: Stifel 2026 Healthcare Conference Date: [...]
Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature
26/10/2026
Study combines AI-guided literature investigation with gene-expression analysis to identify a four-gene signature for Sapu003 development Source: Oncotelic Therapeutics, Inc. AGOURA HILLS, Calif., Oct. 26, 2026 (GLOBE [...]
Novastra Therapeutics Reports Encouraging First Clinical Data for Its Novel XIRT™/OAP Cancer Immune Therapy at ESMO Congress 2026
26/10/2026
Initial data from an investigator-initiated Phase 1 study provide early proof of concept for systematic immune reprogramming therapy (XIRT™) XIRT is built on Novastra’s proprietary OmniAntigen™ Platform (OAP) designed [...]
TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
26/10/2026
COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with [...]
Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline
26/10/2026
Amy Rock, Ph.D., appointed Chief Regulatory and Quality Officer, bringing extensive experience in global regulatory strategy, clinical development, and with approvals of novel immunotherapies Dae Gon Ha, Ph.D., [...]
BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
26/10/2026
CARSON CITY, Nev., Oct. 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases [...]
Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity
26/10/2026
New wholly owned subsidiary, led by Adrian Jones, to expand the Company's network of clinics and pharmacies across Australia VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: [...]
Affordable Pet Labs Launches Nationwide Validation Study of an At-Home Heartworm Test, and Invites Dog Owners in 52 Cities to Help
26/10/2026
More than 1,500 dogs will receive a complete heartworm test from a visiting APL technician at no cost. If the new method meets the current gold standard, APL plans to bring it to pet parents nationwide, direct to [...]
Amwell® to report third quarter 2026 operating results
26/10/2026
BOSTON, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL a leading provider of technology-enabled care, will report third quarter 2026 operating results after stock market trading hours on Tuesday, November 3. [...]
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
26/10/2026
TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile [...]
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
26/10/2026
MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
26/10/2026
COPENHAGEN, Denmark, October 26, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount [...]
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
26/10/2026
— ORPATHYS ® plus TAGRISSO ® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting — — Robust PFS gains alongside [...]
NTG Nordic Transport Group A/S - Upgrade of guidance for the full year 2026
26/10/2026
Company announcement no. 41 – 26 26 October 2026 NTG Nordic Transport Group A/S - Upgrade of guidance for the full year 2026 Based on preliminary financial results for the third quarter of 2026, NTG expects adjusted [...]
Phathom Pharmaceuticals Provides Update on FDA Litigation
26/10/2026
FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum